These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9489596)

  • 1. The time of maximum effect for model selection in pharmacokinetic-pharmacodynamic analysis applied to frusemide.
    Wakelkamp M; Alván G; Paintaud G
    Br J Clin Pharmacol; 1998 Jan; 45(1):63-70. PubMed ID: 9489596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration.
    Wakelkamp M; Alván G; Gabrielsson J; Paintaud G
    Clin Pharmacol Ther; 1996 Jul; 60(1):75-88. PubMed ID: 8689815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of drug input rate on the development of tolerance to frusemide.
    Wakelkamp M; Alván G; Scheinin H; Gabrielsson J
    Br J Clin Pharmacol; 1998 Nov; 46(5):479-87. PubMed ID: 9833602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natriuretic efficiency of frusemide as a consequence of drug input rate.
    Wakelkamp M; Alván G; Paintaud G
    Br J Clin Pharmacol; 1997 May; 43(5):481-91. PubMed ID: 9159563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diuretic effect and diuretic efficiency after intravenous dosage of frusemide.
    Alván G; Helleday L; Lindholm A; Sanz E; Villén T
    Br J Clin Pharmacol; 1990 Feb; 29(2):215-9. PubMed ID: 2306413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of frusemide formulation on diuretic effect and efficiency.
    Wakelkamp M; Blechert A; Eriksson M; Gjellan K; Graffner C
    Br J Clin Pharmacol; 1999 Sep; 48(3):361-6. PubMed ID: 10510147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers.
    Klausner EA; Lavy E; Stepensky D; Cserepes E; Barta M; Friedman M; Hoffman A
    J Clin Pharmacol; 2003 Jul; 43(7):711-20. PubMed ID: 12856384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Input rate as a major determinant of furosemide pharmacodynamics: influence of fluid replacement and hypoalbuminemia.
    Castañeda-Hernández G; Vergés J; Pichette V; Héroux L; Caillé G; du Souich P
    Drug Metab Dispos; 2000 Mar; 28(3):323-8. PubMed ID: 10681377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of the interaction of meloxicam with frusemide in patients with compensated chronic cardiac failure.
    Müller FO; Middle MV; Schall R; Terblanché J; Hundt HK; Groenewoud G
    Br J Clin Pharmacol; 1997 Oct; 44(4):393-8. PubMed ID: 9354315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuation by phenylbutazone of the renal effects and excretion of frusemide in horses.
    Dyke TM; Hinchcliff KW; Sams RA
    Equine Vet J; 1999 Jul; 31(4):289-95. PubMed ID: 10454086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.
    Lesne M
    Arzneimittelforschung; 1988 Jan; 38(1A):160-3. PubMed ID: 3370062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrepancy between bioavailability as estimated from urinary recovery of frusemide and total diuretic effect.
    Alván G; Paintaud G; Eckernäs SA; Grahnén A
    Br J Clin Pharmacol; 1992 Jul; 34(1):47-52. PubMed ID: 1633067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bumetanide and frusemide: a comparison of dose-response curves in healthy men.
    Ramsay LE; McInnes GT; Hettiarachchi J; Shelton J; Scott P
    Br J Clin Pharmacol; 1978 Mar; 5(3):243-7. PubMed ID: 656269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The renin angiotensin aldosterone system and frusemide response in congestive heart failure.
    Reed S; Greene P; Ryan T; Cerimele B; Schwertschlag U; Weinberger M; Voelker J
    Br J Clin Pharmacol; 1995 Jan; 39(1):51-7. PubMed ID: 7756099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the diuretic effects of frusemide and the Karavi Panchaka Ayurveda decoction.
    Welihinda J; Ariyawansa HA; Wickramasinghe R
    Ceylon Med J; 2006 Sep; 51(3):93-7. PubMed ID: 17315585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficiency concept in pharmacodynamics.
    Alván G; Paintaud G; Wakelkamp M
    Clin Pharmacokinet; 1999 May; 36(5):375-89. PubMed ID: 10384860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative study of pharmacokinetics and effects on urinary secretion of electrolytes of furosemide and furosemide-amiloride in healthy subjects].
    Kantelip JP; Aiache JM; Beyssac E; Abella ML
    Therapie; 1991; 46(6):475-9. PubMed ID: 1819153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of indapamide to frusemide increases natriuresis and creatinine clearance, but not diuresis, in fluid overloaded ICU patients.
    Bihari S; Holt AW; Prakash S; Bersten AD
    J Crit Care; 2016 Jun; 33():200-6. PubMed ID: 26948252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic assessment of diuretic efficacy and braking in a furosemide continuous infusion model.
    Adin D; Atkins C; Papich MG
    J Vet Cardiol; 2018 Apr; 20(2):92-101. PubMed ID: 29483040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.